Skip to main content

Citi Reaffirms Their Buy Rating on Zymeworks (ZYME)

Tipranks - Tipranks - Sat Feb 21, 6:28AM CST

In a report released today, Yigal Nochomovitz from Citi maintained a Buy rating on Zymeworks, with a price target of $35.00.

President's Day Sale - 70% Off

According to TipRanks, Nochomovitz is a 3-star analyst with an average return of 2.2% and a 38.41% success rate. Nochomovitz covers the Healthcare sector, focusing on stocks such as Zenas BioPharma, Inc., Olema Pharmaceuticals, and Ultragenyx Pharmaceutical.

In addition to Citi, Zymeworks also received a Buy from TipRanks – Google’s Google Biotechnology in a report issued on February 4. However, on the same day, TipRanks – xAI reiterated a Hold rating on Zymeworks (NASDAQ: ZYME).

See today’s best-performing stocks on TipRanks >>

Based on Zymeworks’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $27.61 million and a GAAP net loss of $19.6 million. In comparison, last year the company earned a revenue of $16 million and had a GAAP net loss of $29.85 million

Read More on ZYME:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).